MX2018010176A - Compuesto novedoso de pirimidina condensada o sal del mismo. - Google Patents
Compuesto novedoso de pirimidina condensada o sal del mismo.Info
- Publication number
- MX2018010176A MX2018010176A MX2018010176A MX2018010176A MX2018010176A MX 2018010176 A MX2018010176 A MX 2018010176A MX 2018010176 A MX2018010176 A MX 2018010176A MX 2018010176 A MX2018010176 A MX 2018010176A MX 2018010176 A MX2018010176 A MX 2018010176A
- Authority
- MX
- Mexico
- Prior art keywords
- salt
- pyrimidine compound
- novel condensed
- condensed pyrimidine
- ret
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
El problema a ser resuelto por la presente invencion es proveer un compuesto novedoso que tiene actividad inhibidora de RET; la presente invencion tambien provee una preparacion farmaceutica que es util para la prevencion y/o tratamiento de enfermedades relacionadas a RET, particularmente cancer, con base en la actividad inhibidora de RET; la presente invencion provee un compuesto representado por la Formula (I): (ver fórmula) en donde A, R2, y X son como se definieron en la especificacion; o una sal del mismo.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016031919 | 2016-02-23 | ||
| JP2016140801 | 2016-07-15 | ||
| PCT/JP2017/006672 WO2017146116A1 (ja) | 2016-02-23 | 2017-02-22 | 新規縮合ピリミジン化合物又はその塩 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018010176A true MX2018010176A (es) | 2019-01-21 |
| MX389450B MX389450B (es) | 2025-03-20 |
Family
ID=59685768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018010176A MX389450B (es) | 2016-02-23 | 2017-02-22 | Compuesto novedoso de pirimidina condensada o sal del mismo. |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US10155768B2 (es) |
| EP (1) | EP3269370B1 (es) |
| JP (1) | JP6273075B1 (es) |
| KR (1) | KR102356212B1 (es) |
| CN (1) | CN108697714B (es) |
| AU (1) | AU2017222908B2 (es) |
| BR (1) | BR112018016724B1 (es) |
| CA (1) | CA3015484C (es) |
| CY (1) | CY1123353T1 (es) |
| DK (1) | DK3269370T3 (es) |
| ES (1) | ES2775751T3 (es) |
| HR (1) | HRP20200352T1 (es) |
| HU (1) | HUE049228T2 (es) |
| IL (1) | IL261107B2 (es) |
| LT (1) | LT3269370T (es) |
| MD (1) | MD3269370T2 (es) |
| ME (1) | ME03669B (es) |
| MX (1) | MX389450B (es) |
| MY (1) | MY199511A (es) |
| PH (1) | PH12018501716A1 (es) |
| PL (1) | PL3269370T3 (es) |
| PT (1) | PT3269370T (es) |
| RU (1) | RU2770727C2 (es) |
| SG (1) | SG11201806930PA (es) |
| SI (1) | SI3269370T1 (es) |
| TW (1) | TWI687422B (es) |
| WO (1) | WO2017146116A1 (es) |
| ZA (2) | ZA201805491B (es) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2012013467A (es) | 2010-05-20 | 2013-04-29 | Array Biopharma Inc | Compuestos macrociclicos como inhibidores de trk cinasa. |
| HRP20211864T1 (hr) | 2015-07-06 | 2022-03-04 | Alkermes, Inc. | Inhibitori hetero-halo histonske deacetilaze |
| US10421756B2 (en) | 2015-07-06 | 2019-09-24 | Rodin Therapeutics, Inc. | Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase |
| WO2017011776A1 (en) | 2015-07-16 | 2017-01-19 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
| MA41559A (fr) | 2015-09-08 | 2017-12-26 | Taiho Pharmaceutical Co Ltd | Composé de pyrimidine condensé ou un sel de celui-ci |
| DK3269370T3 (da) | 2016-02-23 | 2020-04-06 | Taiho Pharmaceutical Co Ltd | Hidtil ukendt kondenseret pyrimidinforbindelse eller salt deraf |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
| MX390582B (es) | 2016-12-28 | 2025-03-20 | Dart Neuroscience Llc Star | Compuestos de pirazolopirimidinona sustituida como inhibidores de fosfodiesterasas 2 (pde2) |
| HRP20220223T1 (hr) | 2017-01-11 | 2022-04-29 | Alkermes, Inc. | Biciklički inhibitori histon deacetilaze |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| CN110267960B (zh) | 2017-01-18 | 2022-04-26 | 阿雷生物药品公司 | 作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡嗪化合物 |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| PL3664802T3 (pl) | 2017-08-07 | 2022-07-11 | Alkermes, Inc. | Bicykliczne inhibitory deacetylaz histonowych |
| AU2018322286B2 (en) | 2017-08-21 | 2022-03-10 | Taiho Pharmaceutical Co., Ltd. | Fusion protein of DCTN1 protein with RET protein |
| TWI876442B (zh) | 2017-10-10 | 2025-03-11 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| DK3717488T3 (da) | 2017-11-27 | 2021-12-13 | Dart Neuroscience Llc | Substituerede furanopyrimidinforbindelser som pde1-inhibitorer |
| EP3740490A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors |
| US11603374B2 (en) | 2018-01-18 | 2023-03-14 | Array Biopharma Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
| CA3087972C (en) | 2018-01-18 | 2023-01-10 | Array Biopharma Inc. | Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors |
| CN112996794A (zh) | 2018-09-10 | 2021-06-18 | 阿雷生物药品公司 | 作为ret激酶抑制剂的稠合杂环化合物 |
| PT3909584T (pt) | 2019-01-11 | 2024-01-12 | Taiho Pharmaceutical Co Ltd | Composto de pirimidina ou um seu sal |
| CN114364798A (zh) | 2019-03-21 | 2022-04-15 | 欧恩科斯欧公司 | 用于治疗癌症的Dbait分子与激酶抑制剂的组合 |
| SG11202111327XA (en) * | 2019-05-13 | 2021-11-29 | Relay Therapeutics Inc | Fgfr inhibitors and methods of use thereof |
| JP2023500906A (ja) | 2019-11-08 | 2023-01-11 | インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） | キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| US11373425B2 (en) | 2020-06-02 | 2022-06-28 | The Nielsen Company (U.S.), Llc | Methods and apparatus for monitoring an audience of media based on thermal imaging |
| WO2022014639A1 (ja) | 2020-07-15 | 2022-01-20 | 大鵬薬品工業株式会社 | Ｅｇｆｒ阻害剤 |
| KR20230031926A (ko) | 2020-07-15 | 2023-03-07 | 다이호야쿠힌고교 가부시키가이샤 | 종양의 치료에 사용되는 피리미딘 화합물을 포함하는 조합 |
| US11763591B2 (en) | 2020-08-20 | 2023-09-19 | The Nielsen Company (Us), Llc | Methods and apparatus to determine an audience composition based on voice recognition, thermal imaging, and facial recognition |
| US11553247B2 (en) | 2020-08-20 | 2023-01-10 | The Nielsen Company (Us), Llc | Methods and apparatus to determine an audience composition based on thermal imaging and facial recognition |
| TW202233625A (zh) | 2020-11-18 | 2022-09-01 | 美商傳達治療有限公司 | Ｆｇｆｒ抑制劑及其製造及使用方法 |
| US20240025910A1 (en) * | 2020-11-20 | 2024-01-25 | Taiho Pharmaceutical Co., Ltd. | Brain-migrating tumor therapeutic agent containing fused pyrimidine compound as active ingredient |
| EP4247379A1 (en) * | 2020-11-20 | 2023-09-27 | Helsinn Healthcare SA | Methods of using 4-amino-n-[4-(methoxymethyl)phenyl]-7-(1-methylcyclopropyl)-6-(3-morpholinoprop-1-yn-1-yl)-7h-pyrrolo[2,3-d]pyrimidine-5-carboxamide for the treatment of tumors |
| WO2022106514A1 (en) * | 2020-11-20 | 2022-05-27 | Helsinn Healthcare Sa | Crystalline forms of 4-amino-n-[4-(methoxymethyl)phenyl]-7-(1-methylcyclopropyl)-6-(3-morpholinoprop-1-yn-1-yl)-7h-pyrrolo[2,3-d]pyrimidine-5-carboxamide, methods of preparation, and uses thereof |
| CN116867492A (zh) * | 2020-11-20 | 2023-10-10 | 赫尔森保健股份公司 | 使用4-氨基-n-[4-(甲氧基甲基)苯基]-7-(1-甲基环丙基)-6-(3-吗啉代丙-1-炔-1-基)-7h-吡咯并[2,3-d]嘧啶-5-羧酰胺治疗肿瘤的方法 |
| US20230233691A1 (en) | 2021-10-22 | 2023-07-27 | University Of Houston System | Methods and compositions for treating chronic inflammatory injury, metaplasia, dysplasia and cancers of epithelial tissues |
| WO2025193959A1 (en) | 2024-03-13 | 2025-09-18 | Fountain Therapeutics Inc. | Methods & compositions for treating dermal atrophy |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6143749A (en) | 1995-06-07 | 2000-11-07 | Abbott Laboratories | Heterocyclic substituted cyclopentane compounds |
| US5665721A (en) | 1995-06-07 | 1997-09-09 | Abbott Laboratories | Heterocyclic substituted cyclopentane compounds |
| UA80171C2 (en) | 2002-12-19 | 2007-08-27 | Pfizer Prod Inc | Pyrrolopyrimidine derivatives |
| WO2005047289A1 (en) | 2003-11-17 | 2005-05-26 | Pfizer Products Inc. | Pyrrolopyrimidine compounds useful in treatment of cancer |
| SI1696920T1 (sl) | 2003-12-19 | 2015-02-27 | Plexxikon Inc. | Spojine in postopki za razvoj modulatorjev ret |
| TW200615268A (en) * | 2004-08-02 | 2006-05-16 | Osi Pharm Inc | Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds |
| EP1968979A2 (en) | 2005-12-08 | 2008-09-17 | Abbott Laboratories | 9-membered heterobicyclic compounds as inhibitors of protein kinases |
| WO2011018894A1 (en) | 2009-08-10 | 2011-02-17 | Raqualia Pharma Inc. | Pyrrolopyrimidine derivatives as potassium channel modulators |
| WO2013059740A1 (en) | 2011-10-21 | 2013-04-25 | Foundation Medicine, Inc. | Novel alk and ntrk1 fusion molecules and uses thereof |
| EP2657233B1 (en) * | 2012-01-19 | 2014-08-27 | Taiho Pharmaceutical Co., Ltd. | 3,5-disubstituted alkynylbenzene compound and salt thereof |
| GB201201566D0 (en) | 2012-01-30 | 2012-03-14 | Vernalis R&D Ltd | New chemical compounds |
| US10031968B2 (en) | 2012-10-11 | 2018-07-24 | Veveo, Inc. | Method for adaptive conversation state management with filtering operators applied dynamically as part of a conversational interface |
| WO2014130975A1 (en) | 2013-02-22 | 2014-08-28 | Bastian Boris C | Fusion polynucleotides and fusion polypeptides associated with cancer and particularly melanoma and their uses as therapeutic and diagnostic targets |
| JP6397897B2 (ja) * | 2013-05-14 | 2018-09-26 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | ピロロ［２，３−ｄ］ピリミジン誘導体、その製造方法及びキナーゼ阻害剤としてのその使用 |
| MX360498B (es) | 2013-08-12 | 2018-11-05 | Taiho Pharmaceutical Co Ltd | Compuesto novedoso de pirimidina fusionada o sal del mismo. |
| WO2015078417A1 (zh) | 2013-11-29 | 2015-06-04 | 四川好医生药业集团有限公司 | 吡咯并嘧啶化合物及其在制备降血糖药物中的用途 |
| JP6141568B1 (ja) * | 2015-09-01 | 2017-06-07 | 大鵬薬品工業株式会社 | 新規なピラゾロ［３，４−ｄ］ピリミジン化合物又はその塩 |
| MA41559A (fr) * | 2015-09-08 | 2017-12-26 | Taiho Pharmaceutical Co Ltd | Composé de pyrimidine condensé ou un sel de celui-ci |
| DK3269370T3 (da) * | 2016-02-23 | 2020-04-06 | Taiho Pharmaceutical Co Ltd | Hidtil ukendt kondenseret pyrimidinforbindelse eller salt deraf |
-
2017
- 2017-02-22 DK DK17756554.6T patent/DK3269370T3/da active
- 2017-02-22 HR HRP20200352TT patent/HRP20200352T1/hr unknown
- 2017-02-22 AU AU2017222908A patent/AU2017222908B2/en active Active
- 2017-02-22 JP JP2017519012A patent/JP6273075B1/ja active Active
- 2017-02-22 WO PCT/JP2017/006672 patent/WO2017146116A1/ja not_active Ceased
- 2017-02-22 MX MX2018010176A patent/MX389450B/es unknown
- 2017-02-22 ES ES17756554T patent/ES2775751T3/es active Active
- 2017-02-22 LT LTEP17756554.6T patent/LT3269370T/lt unknown
- 2017-02-22 CN CN201780012909.0A patent/CN108697714B/zh active Active
- 2017-02-22 PL PL17756554T patent/PL3269370T3/pl unknown
- 2017-02-22 CA CA3015484A patent/CA3015484C/en active Active
- 2017-02-22 SG SG11201806930PA patent/SG11201806930PA/en unknown
- 2017-02-22 SI SI201730182T patent/SI3269370T1/sl unknown
- 2017-02-22 EP EP17756554.6A patent/EP3269370B1/en active Active
- 2017-02-22 PT PT177565546T patent/PT3269370T/pt unknown
- 2017-02-22 ME MEP-2020-46A patent/ME03669B/me unknown
- 2017-02-22 BR BR112018016724-0A patent/BR112018016724B1/pt active IP Right Grant
- 2017-02-22 RU RU2018133000A patent/RU2770727C2/ru active
- 2017-02-22 MD MDE20180076T patent/MD3269370T2/ro unknown
- 2017-02-22 KR KR1020187027127A patent/KR102356212B1/ko active Active
- 2017-02-22 TW TW106105968A patent/TWI687422B/zh active
- 2017-02-22 MY MYPI2018702960A patent/MY199511A/en unknown
- 2017-02-22 IL IL261107A patent/IL261107B2/en unknown
- 2017-02-22 HU HUE17756554A patent/HUE049228T2/hu unknown
- 2017-09-19 US US15/708,917 patent/US10155768B2/en active Active
-
2018
- 2018-08-13 PH PH12018501716A patent/PH12018501716A1/en unknown
- 2018-08-16 ZA ZA201805491A patent/ZA201805491B/en unknown
- 2018-11-01 US US16/177,844 patent/US10807986B2/en active Active
-
2019
- 2019-08-13 ZA ZA2019/05332A patent/ZA201905332B/en unknown
-
2020
- 2020-03-26 CY CY20201100282T patent/CY1123353T1/el unknown
- 2020-05-13 US US15/930,554 patent/US11046696B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018010176A (es) | Compuesto novedoso de pirimidina condensada o sal del mismo. | |
| MX2018002889A (es) | Compuesto de pirimidina fusionada o sal del mismo. | |
| CL2019000844A1 (es) | Compuesto de piridina. | |
| CY1123059T1 (el) | Αναστολη του διαυλου ιοντων παροδικου δυναμικου του υποδοχεα α1 | |
| NI201600144A (es) | Derivados de quinoxalina utiles como moduladores del fgfr cinasa | |
| BR112016029916A2 (pt) | inibidores mnk e métodos correlatos | |
| BR112017002001A2 (pt) | compostos e composição farmacêutica | |
| PE20151542A1 (es) | Compuestos de tetrahidropirrolotiazina | |
| MX2018016193A (es) | Métodos para el tratamiento del cáncer de ovario. | |
| BR112016023558A2 (pt) | compostos úteis como imunomoduladores | |
| MX2016013689A (es) | Compuestos 4-amino-imidazoquinolina. | |
| MX381235B (es) | Análogos de éter fosfolipídico como portadores de fármacos dirigidos a cáncer. | |
| NI201700056A (es) | 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1 para el tratamiento de la enfermedad de alzhéimer | |
| EA201590255A1 (ru) | КОНДЕНСИРОВАННЫЕ ПИРИМИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ КОМПЛЕКСА p97 | |
| DOP2016000194A (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
| MX2016011072A (es) | Derivado de pirazol amida. | |
| DOP2019000193A (es) | Nuevo compuesto heterocíclico, su método de preparación y composición farmacéutica que lo comprende | |
| MX2019003026A (es) | Compuestos de heteroarilcarboxamida como inhibidores de ripk2. | |
| MX377528B (es) | Compuestos de platino funcionalizados con monomaleimida para la terapia del cáncer. | |
| MX383975B (es) | Derivado de anillo fusionado como inhibidor del receptor a2a | |
| CO2017007076A2 (es) | Compuestos de indenilo, composiciones farmacéuticas y usos médicos del mismo | |
| CL2016000884A1 (es) | Derivados de piperazina y su uso como medicamento. | |
| MX2018009458A (es) | Derivado de sulfonamida heterociclico y medicina que contiene el mismo. | |
| CL2020001093A1 (es) | Proceso para preparar el benzotiofen-2-il boronato. | |
| DOP2019000194A (es) | Derivados de pirrolotriazina como inhibidor de cinasas |